A Randomized, Controlled, First-in-Human Study of AP31969 on Single and Multiple Ascending Doses and Food Effect in Healthy Subjects with Atrial Fibrillation

The primary objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of **AP31969** in healthy subjects. This investigation is crucial for understanding the potential therapeutic application of AP31969 in managing **Atrial Fibrillation**, a common form of cardiac arrhythmia. By assessing the drug's effects in a controlled environment, the study aims to establish a foundational understanding of its pharmacological profile, which is essential for future clinical applications in patients with atrial fibrillation.

The clinical trial involves participants diagnosed with **Atrial Fibrillation**, a common cardiac arrhythmia. The study population includes both male and female subjects, with an age range categorized under code "3," which typically represents adults. The trial also includes a vulnerable population, although specific details regarding the nature of this vulnerability are not provided. The sponsor has not disclosed the total number of participants involved in the study. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been specified. The absence of detailed inclusion or exclusion criteria suggests that the sponsor has not provided this information.

The clinical trial is designed as a **randomized**, **controlled**, first-in-human study to evaluate the safety and pharmacokinetics of AP31969 in healthy subjects. The trial will investigate both single and multiple ascending doses, as well as the effect of food on the drug's absorption. The study is set to commence recruitment on October 3, 2023, and is expected to conclude by June 16, 2024. The trial is categorized as a Phase 1 study, focusing on the initial assessment of the investigational product in humans.

Participants will undergo a series of study visits, beginning with an inclusion visit, which serves as the screening phase to determine eligibility based on predefined criteria. Following successful screening, subjects will be randomized into different dosing groups. The trial will include multiple follow-up visits to monitor safety, collect pharmacokinetic data, and assess any adverse events. The end-of-study visit will mark the completion of the participant's involvement, where final assessments will be conducted to ensure the well-being of the subjects and gather concluding data.

The expected duration of participant involvement will vary depending on the dosing schedule and the number of follow-up visits required. However, the overall participation period is anticipated to align with the trial's estimated end date. Conditions that may lead to early termination from the study include the occurrence of significant adverse events, non-compliance with study procedures, or withdrawal of consent by the participant. The trial aims to provide valuable insights into the safety profile and pharmacokinetic properties of AP31969, contributing to the understanding of its potential therapeutic application in conditions such as **atrial fibrillation**.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it has an **orphan drug** designation. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this study, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used alongside the experimental medication. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. Consequently, the trial documentation lacks comprehensive information on the treatment protocols and participant management strategies.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, with an estimated recruitment start date of October 3, 2023, and an estimated end date of June 16, 2024. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, the trial will likely involve systematic data collection and analysis to determine the treatment's impact. The methods for measuring and analyzing efficacy will adhere to standard clinical trial protocols, ensuring the reliability and validity of the results. The trial's design will focus on gathering comprehensive data to evaluate the treatment's effectiveness, contributing to the overall understanding of its potential benefits.